化学因子受体6（CCR6）是一种G蛋白偶联受体（GPCR），参与多种生物过程。当CCR6与其唯一的配体CCL20结合时，形成一个信号网络。该途径与许多疾病的机制有关，如癌症、牛皮癣、多发性硬化症、艾滋病感染或类风湿关节炎等。CCR6/CCL20轴在免疫稳态和激活中发挥着基本作用。Th17细胞表达CCR6受体和炎性细胞因子，包括IL-17、IL-21和IL-22，这些因子参与炎症反应的扩散。CCL20/CCR6机制在这些促炎性细胞进入局部组织中的招募中发挥关键作用。迄今为止，没有批准针对CCR6的药物，并且由于筛选的困难性，开发针对CCR6的小分子化合物很困难。本综述突出了CCR6受体在许多疾病中作为治疗靶点的潜力，以及开发针对CCR6的抗体的重要性，这可以是CC6 / CCL20轴相关病理治疗中小分子化合物的有希望的替代方案。

The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor (GPCR) involved in a wide range of biological processes. When CCR6 binds to its sole ligand CCL20, a signaling network is produced. This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple sclerosis, HIV infection or rheumatoid arthritis. The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. Th17 cells express the CCR6 receptor and inflammatory cytokines, including IL-17, IL-21 and IL-22, which are involved in the spread of inflammatory response. The CCL20/CCR6 mechanism plays a crucial role in the recruitment of these pro-inflammatory cells to local tissues. To date, there are no drugs against CCR6 approved, and the development of small molecules against CCR6 is complicated due to the difficulty in screenings. This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases and the importance of the development of antibodies against CCR6 that could be a promising alternative to small molecules in the treatment of CCR6/CCL20 axis-related pathologies.